Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

PHASE4RecruitingINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Chemotherapy-Induced Febrile Neutropenia
Interventions
DRUG

QL0605(PEG-rhG-CSF)

Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.

DRUG

QL0605(PEG-rhG-CSF)

Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.

Trial Locations (1)

250117

RECRUITING

Shandong Cancer Hospital, Jinan

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06616571 - Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints | Biotech Hunter | Biotech Hunter